Bristol-Myers Squibb and Incyte to launch new cancer drug trials

Bristol-Myers Squibb and Incyte have announced plans to take their new combination therapy of Opdivo and epacadostat into first-line registrational trials.

The companies will advance their clinical development programme evaluating the combination of epacadostat and Opdivo into phase III registrational studies in first-line non-small cell lung cancer across the spectrum of PD-L1 expression, as well as first-line head and neck cancer.

Additionally, the companies are expanding the ECHO-204 phase I/II study, established under a collaboration between the companies in 2014, to include anti-PD-1/PD-L1 relapsed/refractory melanoma cohorts.

The expanded clinical development programme including the phase III registrational studies, will be co-funded by both partners and will help bring them a step closer to delivering new and improved treatment options for a range of cancers.

Dr Fouad Namouni, head of development for oncology at Bristol-Myers Squibb, said: "Incyte shares our goal of improving clinical outcomes for patients with some of the hardest-to-treat cancers, and we look forward to working together on studies evaluating the clinical outcomes of this therapeutic combination."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.